SEARCH · PubMed Health

Results for “PROLACTIN”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources

PubMed1976

Comparative immunological studies between canine prolactin and prolactin from other species.

Canine pituitary extracts contained material which was capable of inhibiting the binding between antisera to different prolactins and labelled non-canine prolactins. Maximum inhibition of binding was observed in the system consisting of antisera to ovine prolactin and labelled rat prolactin. This system was used to investigate the immunological activity of canine pituitary extracts and partially purified fractions. A rabbit antiserum which was raised against a canine pituitary extract and had significant immunological activity in the above system, together with labelled rat prolactin, was used to develop an assay capable of detecting material in canine pituitary extracts. This material gave parallel dose-response curves to a canine prolactin-rich fraction, D864C and purified ovine and bovine prolactin.

Animals↗

PubMed1985

Serum prolactin levels in women with excessive milk production. Normalization by transitory prolactin inhibition.

Serum prolactin levels and milk yield were studied in 27 puerperae with excessive milk production (polygalactia) and compared with 30 normally lactating puerperae. In order to normalize polygalactia, 14 of these women were treated with 2.5 mg bromocriptine per day for 3 days starting on post-partum day 5, 13 women received placebo. Milk flow in polygalactic women started significantly earlier than in puerperae with normal milk yield and developed mean milk volumes of 816 g per day on post-partum day 4. Serum prolactin levels did not differ from levels of puerperae with normal milk yield. There was no correlation between serum prolactin and milk yield. Bromocriptine treatment resulted in a sharp but reversible decline of serum prolactin levels followed by a significant reduction of milk production. Bromocriptine could not be detected in milk specimens, while serum levels showed significant amounts. In placebo treated women prolactin levels and milk yield remained unaffected. These data indicate that serum prolactin concentrations of puerperae with polygalactia are within the normal post-partum range. Short term prolactin suppression by bromocriptine can reduce milk yield, without complete ablactation.

Bromocriptine↗

PubMed1991

Changes in plasma progesterone and prolactin concentrations during the annual cycle and the role of prolactin in the maintenance of lactation and luteal development in the Antarctic fur seal (Arctocephalus gazella).

Progesterone in Antarctic fur seals was undetectable from 1-2 days before parturition to 4-6 days after parturition. There was a rapid increase in progesterone to 20 ng/ml between 6 and 10 days post partum and this increase coincided with peak concentrations of oestradiol-17 beta at the time normally associated with oestrus and mating in this species. Newly formed corpora lutea were present in the ovaries by Day 9 post partum even though the seals had been isolated in an enclosure and not mated. Thereafter, progesterone remained detectable, but at a low concentration (5 ng/ml) throughout embryonic diapause. A similar pattern was observed in unmated females which suggests they enter a period of pseudopregnancy. Progesterone increased to 35 ng/ml between late February and mid-March, indicating activation of the corpus luteum at the end of diapause, and then declined slowly through the remainder of gestation. Plasma prolactin, measured against a human prolactin standard, was elevated from 1-2 days before parturition and peaked at 0-3 days post partum. It then declined slowly throughout the post-partum period and remained at a low level throughout embryonic diapause. Prolactin concentration declined to undetectable at the end of diapause and before the end of lactation. Reduction of prolactin secretion by injections of bromocriptine from Days 3 to 5 post-partum terminated lactation. Mothers, which normally leave their pups to feed at sea on about Day 7 post partum, did not continue to lactate beyond Day 7 although this did not appear to be associated with reduced prolactin secretion. Bromocriptine treatment appeared to prevent the post-ovulatory surge of progesterone although there was no long-term effect of bromocriptine on progesterone secretion during the early stages of embryonic diapause/pseudopregnancy. This study has shown that prolactin is an important hormone for maintaining early lactation in the fur seal and it probably also has a role in the control of ovulation and luteal development. Prolactin does not appear to be implicated in the control of lactation cycles in fur seals. Changes in plasma progesterone during the annual cycle show that the pattern in fur seals resembles that of some carnivores with embryonic diapause.

Animals↗

PubMed1996

Cloning of rabbit prolactin cDNA and prolactin gene expression in the rabbit mammary gland.

cDNA clones coding for rabbit prolactin were isolated from a pituitary library using a rat prolactin RNA probe. One cDNA contained 873 bases including the entire coding sequence of rabbit prolactin, its signal peptide and the 5' and 3' untranslated regions of 44 and 145 nucleotides respectively. The deduced amino acid sequence of the cloned prolactin cDNA presented a 93-78% identity with mink, porcine and human prolactins. The prolactin gene transcription was investigated by RT-PCR analysis in several organs of midlactating New Zealand White rabbits. The ectopic transcription of the prolactin gene was examined in more detail in the mammary gland. A strong PCR signal was detected in the mammary gland of virgin does and was also observed during pregnancy and at the beginning of lactation. This PCR signal was very weak in mid-lactating and absent in post-weaning mammary gland.

Amino Acid Sequence↗

PubMed1985

Responses to prolactin secretagogues in oestrogen-treated rats suggest that the defect in prolactin regulation produced by oestrogen is at the level of the pituitary gland.

Prolactin responses to pharmacological agents were used to characterize the defect in prolactin regulation which occurs after administration of high doses of oestrogen to rats. Animals with chronically implanted venous cannulae were injected with 2 mg oestradiol benzoate in oil and 2-3 days later prolactin concentrations were measured after injections of saline, thyrotrophin-releasing hormone (TRH), fenfluramine, apomorphine and butaclamol. The responses were compared with those in oil-injected animals. Hyperprolactinaemia in oestrogen-treated animals was unresponsive to apomorphine, but was even more sensitive to dopamine receptor blockade than controls. These results suggest that the lactotrophs in oestrogen-treated animals are already maximally suppressed by endogenous dopamine, though ineffectively. Although there was an increased prolactin response to TRH in oestrogen-treated animals, there was an impaired response to fenfluramine, indicating suppressed serotonergic prolactin-releasing factor mechanisms. Maximal endogenous dopaminergic activity and suppressed prolactin-releasing factor mechanisms are appropriate hypothalamic responses to hyperprolactinaemia. The operation of these responses in the earliest stages of the development of pituitary hyperplasia indicates that oestrogen induces a disturbance of prolactin regulation in the lactotroph, independent of hypothalamic control.

Animals↗

PubMed1986

Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats.

Relationships among the release of prolactin, the effect of oestrogens and the proliferation of prolactin-secreting cells were studied under several experimental conditions. Administration of sulpiride or oestradiol released prolactin and stimulated cell proliferation in the anterior pituitary gland of adult male rats. Clomiphene completely abolished the rise in cell proliferation, but did not interfere with the sulpiride-induced release of prolactin. Treatment with oestradiol plus sulpiride significantly increased serum prolactin concentrations and the mitotic index compared with the sum of the stimulation produced by both drugs separately. Bromocriptine abolished the stimulatory effect of oestradiol on the serum prolactin concentration and on cell proliferation. In oestradiol- and/or sulpiride-treated rats, 80% of the cells in mitoses were lactotrophs. The remaining 20% did not stain with antisera against any of the pituitary hormones. The number of prolactin-secreting cells in the anterior pituitary gland significantly increased after the administration of oestradiol or sulpiride. The results demonstrate that treatment with sulpiride and/or oestradiol increases the proliferation and the number of lactotrophs in the anterior pituitary gland of the rat.

Animals↗

PubMed1987

Influence of a prolactin- and ACTH-secreting tumour on oestrous cyclicity, the pro-oestrous surges of LH and prolactin and ovarian hypertrophy in the rat.

These studies were designed to investigate the effects of a prolactin- and ACTH-secreting tumour (7315a) on reproductive cyclicity, pro-oestrous surges of LH and prolactin and ovarian hypertrophy in the rat. Normal adult Buffalo rats, which are syngeneic to the 7315a tumour, were found to have a significant pro-oestrous prolactin surge and a relatively low-level preovulatory LH surge. Within 14 days of s.c. injection of dispersed tumour cells, a small tumour was detectable by palpation in one rat, but measurable tumours were not observed until day 18. The pro-oestrous surge of LH, but not of prolactin, was effectively suppressed by day 17. Cessation of reproductive cyclicity (anoestrus) was apparent within 19.4 +/- 1.1 days of injection of tumour cells. Removal of a single ovary showed that there was no change in ovarian weight before anoestrus in the tumour-bearing animals. Subsequent hypertrophy of the second ovary was augmented during the early stages of tumour development (days 8 and 13), and this corresponded to the unexpected finding that the gonadotrophin surges on days 8 and 13 were significantly increased when compared with controls. Ovarian hypertrophy was not significantly different from that in controls after suppression of the gonadotrophin surge (day 17). The results suggest that inhibition of the preovulatory LH surge might be a critical event in the tumour-induced cessation of reproductive cyclicity. The fact that pre-surge concentrations of prolactin did not increase substantially until the conspicuous onset of tumour prolactin secretion on day 21 indicated that the preovulatory LH surge might be inhibited by relatively low levels of tonically secreted prolactin.

Adrenocorticotropic Hormone↗

PubMed2002

Prolactin-releasing peptide in the ewe: cDNA cloning, mRNA distribution and effects on prolactin secretion in vitro and in vivo.

RT-PCR followed by 5'- and 3'- rapid amplification of cDNA ends was used to clone and sequence ovine prolactin-releasing peptide (PrRP). The cDNA was characterised by short 5'- and 3'-untranslated regions and a GC-rich (71%) coding region. The nucleotide and deduced amino acid sequences for the coding region showed 95.6 and 94.9% identity with bovine PrRP but the amino acid sequence of PrRP31 was conserved between these species. Northern blot analysis and RT-PCR showed that, as in the rat, the peptide was more abundantly expressed in the brainstem than the hypothalamus. However, in the ovine hypothalamus, PrRP mRNA expression was more widespread than in the rat, with expression detected in both rostral and caudal parts of the mediobasal hypothalamus. The effects of synthetic ovine PrRP on prolactin secretion both in vitro and in vivo were also examined. In primary cultures of sheep pituitary cells, PrRP significantly (P<0.01) increased prolactin concentrations in the culture medium but the response was not observed in every experiment and was only seen when pituitary glands were dispersed with collagenase rather than trypsin. PrRP was much less potent than TRH which caused a significant (P<0.01) two- to threefold increase in prolactin concentrations in every experiment. Intravenous (10 and 50 nmol) or intracerebroventricular (10 and 50 nmol) injection of PrRP had no significant effect on either plasma prolactin concentration or pulsatile LH secretion whereas intravenous injection of TRH (10 nmol) produced a highly significant (P<0.01) and more than sevenfold stimulation of plasma prolactin concentrations. In conclusion, these results suggest that PrRP is unlikely to be an important prolactin-releasing factor in this species.

Amino Acid Sequence↗

PubMedDate not supplied

[Monoclonal antibodies to bovine prolactin interacting with human prolactin].

Two stable hybridomas producing antibodies (Mab 1 and Mab 2) to bovine prolactin and belonging to the IgG1 subclass have been prepared. The cross-reactivity of Mab 1 and Mab 2 with some structurally similar pituitary protein (human, pig, whale, rat prolactins, bovine and human somatotropins) using indirect immunoenzymatic assay, was studied. It has been shown that Mab 2 reacts specifically only with bovine prolactin whereas Mab 1 interacts with human prolactin and prolactins of different animals. The specificity of Mab 1 to human prolactin was confirmed by immunoradiodetection assay on nitrocellulose filters. The data obtained give evidence of the existence of at least two different sterically nonoverlapping epitopes: one of them is specific exclusively for bovine prolactin and the other one is common, i.e. extraspecific.

Animals↗

PubMed1989

[The lysosomal pathway of prolactin degradation in the mammary gland: kinetics of prolactin hydrolysis by cathepsin D and the peptides formed thereby].

Some peculiarities of prolactin hydrolysis by rat mammary gland lysosomal proteinases were studied. It was demonstrated that at pH 3.0-3.7 the initial steps of prolactin hydrolysis are under control of cathepsin D. Cysteine cathepsins are responsible for the deep degradation of the peptides formed. The molecular mass of rat mammary gland cathepsin D as determined by chromatography on Sephadex G-100 is about 45 kDa. Using affinity chromatography on hemoglobin-Sepharose 4B, cathepsin D was purified 300--320-fold. The purified enzyme rapidly hydrolyzes low concentrations of prolactin down to peptides with Mr less than 1 kDa. At substrate--enzyme concentration ratios above 3:1, the limited proteolysis of prolactin occurred. At early steps of prolactin hydrolysis the formation of two peptides (Mr approximately 10 kDa) takes place. Deeper degradation of sheep prolactin led to the formation of four peptides with molecular masses of 6630, 3020, 1880 and 1040 Da (data from SDS-PAGE electrophoresis). An analysis of structural peculiarities of prolactin from different animal species revealed that this hormone is protected from the damaging effect of exopeptidases.

Amino Acid Sequence↗

PubMed1988

Ultrastructural morphology of nontumorous prolactin cells in human pituitaries harboring prolactin-producing adenoma.

To study the effect of hyperprolactinemia on nontumorous prolactin cells, their morphology was investigated by transmission electron microscopy and morphometry in the nontumorous portion of seven human pituitaries containing prolactin-producing adenoma. For cell identification, immunoelectron microscopy was applied using the immunogold labelling method. In five cases, nontumorous prolactin cells demonstrated features of inactivity, whereas in two cases they showed morphological features of active hormone secretion. Our findings are consistent with the view that prolactin regulates its own release from prolactin cells in the anterior pituitary via the short loop negative feedback mechanism. Hyperprolactinemia presumably activates the short loop feedback mechanism resulting in inhibition of nontumorous prolactin cell. However, in two cases, hyperactivity of nontumorous prolactin cells was observed suggesting a dysfunction of the feedback mechanism.

Adenoma↗

PubMed1983

Prolactin molecular heterogeneity. Response to thyrotropin-releasing hormone stimulation of concanavalin A-bound and -unbound immunoassayable prolactin during human pregnancy.

Since the milieu of pregnancy stimulates physiologic hyperprolactinemia, we questioned whether prolactin secreted during normal pregnancy contains a large-molecular weight component that binds to concanavalin A and whether this large-molecular weight prolactin contributes to the thyrotropin-releasing hormone (TRH)-releasable pool. Serum was collected from pregnant patients (n = 28) undergoing TRH stimulation tests. This serum was passed through a concanavalin A column and eluted with 0.2M alpha-methylmannoside. Concanavalin A-bound prolactin, as determined by radioimmunoassay, ranged from 10% to 30% of the total immunoassayable prolactin. An increase in the basal serum concentration of both concanavalin A-bound and -unbound prolactin occurred as pregnancy progressed. However, throughout gestation, only the concanavalin A-unbound prolactin increased after TRH stimulation. The concanavalin A-bound prolactin was found to have a molecular weight of 60,000 by means of Sephadex G-100 permeation chromatography.

Concanavalin A↗

PubMed1984

Effect of prolactin and relaxin on in vitro rat uterine contractions and prolactin interaction with relaxin.

The balance between relaxin and prolactin has been suggested to be significant in the control of uterine activity during pregnancy. The current study was designed to determine the effect of rat prolactin on rat uterine horn segment contractility and its interaction with relaxin. Rat uterine segments mounted on a smooth muscle transducer were treated sequentially with prolactin and relaxin, and stimulated electrically. No stimulatory effect of prolactin was noted. Relaxin-inhibited uterine horn segment activity was not altered by prolactin. The reported stimulatory effect of prolactin may have been a pharmacologic effect of human prolactin on rat uterine horn segments, or may have resulted from contaminants in the preparations used.

Animals↗

PubMed1996

Effect of estrogen and neuroleptics on prolactin secretion and immunoreactive prolactin cells.

The use of estrogen and dopamine receptor antagonists is associated with elevated prolactin levels and, in rats, chronic estrogen treatment is also associated with lactotroph proliferation. In this study, haloperidol, fluphenazine, sulpiride and metoclopramide, alone or combined with estradiol, were administered to Wistar rats. Pituitary weight, serum prolactin levels and percent of immunoreactive prolactin cells in the anterior pituitary glands were determined at the end of 60 days of treatment. The pituitary weight of rats treated with estrogen alone or in combination with other drugs was significantly higher than the control group. The serum prolactin level was higher than the upper confidence limit in all but three of the 90 treated rats. While in the control group the percent of immunoreactive prolactin cells was 20%, administration of the neuroleptic drugs and metoclopramide increased this percent to approximately 30%, and estrogen alone or in combination with one of the neuroleptic drugs increased it to approximately 40%. The results presented here demonstrate the relationship between prolactin secretion and prolactin cell number when different neuroleptics and related drugs are used.

Animals↗

PubMed1985

Concentration of native prolactin and prolactin binding sites in hepatic subcellular fractions from hyperprolactinemic rats.

Lactogen binding and prolactin content were measured in hepatic subcellular fractions from tumor-bearing rats (TBR; MtT/F4, MtT/W5, MtT/W10) with elevated prolactin and growth hormone levels and from control animals. Specific binding of 125I-oPRL to Golgi fractions from tumor-bearing animals was 2.5 to 7 fold greater than that from controls. Binding to plasmalemma was 6-fold greater in tumor-bearing rats. The specific binding of 125I-labelled bGH and insulin showed less marked differences between TBR and controls. Subcellular fractions were extracted with HCl to determine hormonal content. The content of prolactin and growth hormone in Golgi fractions from TBR was at least 20-fold that in fractions from controls. Rat prolactin extracted from Golgi heavy elements was 50% as effective as native material in binding to lactogen receptors as judged by radioreceptor assay. These studies demonstrate that the chronic elevation of prolactin was associated with an increase of receptors not only in the intracellular compartment but on the cell surface as well. Furthermore, they demonstrate that native prolactin is internalized and accumulated in rat liver Golgi fractions.

Animals↗

PubMed1985

Prolactin increases lipid fluidity and prolactin binding of rat prostatic membranes.

The objective of these studies was to determine whether prolactin could modify the lipid fluidity of rat ventral and dorsolateral prostate membranes and subsequently modify the availability of prolactin receptors. Additional studies were also undertaken to determine the effects of prolactin on serum lipid fluidity. Adult male rats were injected with 0, 100, or 400 micrograms ovine prolactin/day subcutaneously for a period of 5 days. Serum and prostatic membrane lipid fluidity was measured by a fluorescence polarization method using a lipid probe 1,6-diphenylhexatriene. Prolactin binding in dextran-coated charcoal-pretreated prostatic membranes was determined by radioreceptor assay. This pretreatment has been reported by us to remove the endogenous substances that interfere with prolactin binding assay (J. R. Dave and R. J. Witorsch, Endocrinology 111: 2144-2146, 1982). Prolactin binding increased by approximately 44 and 72% in dorsolateral prostate and 16 and 39% in ventral prostate in 100- and 400-micrograms groups, respectively. Membrane fluidity increased by approximately 16 and 19% in dorsolateral prostate and 10 and 13% in ventral prostate in 100- and 400-micrograms groups, respectively. Serum lipid fluidity increased 50 and 79% in 100- and 400-micrograms groups, respectively.

Animals↗

PubMed1998

Is prolactin a gonadotrophic hormone in red deer (Cervus elaphus)? Pattern of expression of the prolactin receptor gene in the testis and epididymis.

This study investigated the pattern and site of expression of the prolactin receptor gene in the testis and epididymis of red deer collected during the breeding season (n=3). Ribonuclease protection assays using 50 microg total RNA and a 300 bp [32P]-labelled antisense cRNA probe, generated from the extracellular domain of the red deer prolactin receptor, confirmed the expression of the receptor in both the testis and epididymis; a higher level of prolactin receptor mRNA was detected in the epididymis compared with the testis (170.4+/-1.5 x 10(3) and 26.3+/-2.7 x 10(3) arbitrary units respectively; P<0.05). In situ hybridisation using 300 bp [33P]-labelled sense and antisense cRNA probes generated from the extracellular domain of the receptor localised the expression sites to the seminiferous tubules and interstitial compartments of the testis and the epithelial layer of the epididymal duct. Quantification of grain numbers demonstrated a higher level of expression of the receptor in the epididymis compared with the interstitial and seminiferous tubule compartments of the testis (18.1+/-4.4 x 10(2), 10.1+/-2.0 x 10(2) and 8.3+/-0.8 x 10(2) grains/microm2 respectively; P<0.05). However, no differences were detected in the level of expression of the receptor between the interstitial and seminiferous tubule compartments of the testis. Immunocytochemistry using an anti-prolactin receptor antibody, raised against a peptide sequence from the extracellular domain of the rat prolactin receptor, localised expression of the receptor gene to the Leydig cells, pachytene spermatocytes, round spermatids and elongating spermatids. In the epididymis, the receptor was localised to the epithelial layer within the epididymal ducts. Expression of the prolactin receptor gene in the red deer testis and epididymis suggests a role for the hormone in steroidogenesis and spermatogenesis.

Animals↗

PubMed1998

Alternative splicing of the prolactin receptor gene generates a 1.7 kb RNA transcript that is linked to prolactin function in the red deer testis.

A cDNA encoding a putative non-membrane bound prolactin receptor was amplified by RT-PCR from red deer (Cervus elaphus) testis. Sequence analysis suggests that the testicular cDNA is generated by alternative splicing resulting in the deletion of exons 7 and 8, which code for: (a) the final 53 aa of the extracellular domain of the receptor including the fifth conserved cysteine residue and the WS x WS motif, (b) the entire transmembrane domain, (c) the first three cytoplasmic amino acid residues, and (d) two nucleotides of the fourth cytoplasmic amino acid codon. The resultant RNA would encode a putative protein of 174 aa due to a single bp frame shift and a premature stop codon. Northern blot analysis confirmed that the PCR-amplified cDNA is encoded by a specific 1.7 kb RNA transcript whereas the membrane bound receptor is encoded by transcripts of 3.5 and 2.5 kb. HPLC studies using media from 293 cells transfected with the 1.7 kb cDNA failed to detect any specific binding for prolactin. These data suggest that: (a) the deletion in the 1.7 kb transcript alters the structure of the prolactin binding domain in the putative protein encoded by the 1.7 kb transcript, and (b) alternative splicing of the prolactin receptor gene toward the 1.7 kb transcript is a means of down-regulating the expression of the full length prolactin receptor and hence may modify the role of prolactin in the testis of seasonally breeding mammals such as red deer. The sequence reported in this paper has been deposited in the Genbank/EMBL data base with accession number Y14753.

Alternative Splicing↗